Why carry out this study?
|
Janus kinase (JAK) inhibitors have been linked to a possible class effect associated with particular adverse events, such as major adverse cardiovascular event (MACE), venous thromboembolism (VTE), and malignancy. |
Further characterisation of adverse events of special interest (AESI) for JAK inhibitors in at-risk populations will improve benefit–risk assessment for individual patients and diseases. |
This analysis examines AESI in the baricitinib clinical programmes for rheumatoid arthritis, atopic dermatitis, and alopecia areata for patients with low risk (younger than 65 years with no specified risk factors), and patients at risk (at least one of: aged 65 years or older, atherosclerotic cardiovascular disease, diabetes mellitus, hypertension, current smoking, HDL cholesterol <40 mg/dL, BMI ≥ 30 kg/m2, poor mobility on EQ-5D, or history of malignancy). |
What was learned from this study?
|
Incidence of AESI in patients treated with baricitinib who were younger than 65 years without risk factors were reduced compared with the population of patients with risk factors for all indications, and the number of AESI is also minimal for patients with atopic dermatitis and alopecia areata who have risk factors. |
Individual disease burden, risk factors, and response to treatment should be considered to make informed decisions for individual patients treated with baricitinib. |
Introduction
Methods
RA Analysis Set
AD Analysis Set
AA Analysis Set
Compliance with Ethics Guidelines
Statistical Analysis
Results
RA N = 3770, PYR = 14,744 | AD N = 2636, PYR = 4628 | AA N = 1303, PYR = 1868 | |
---|---|---|---|
ASCVD | 119 (3.2) | 25 (0.9) | 12 (0.9) |
Current smoker | 603 (16.0) | 634 (24.1) | 222 (17.0) |
Hypertension | 1348 (35.8) | 349 (13.2) | 145 (11.1) |
HDL < 40 mg/dL | 308 (8.2) | 360 (13.7) | 116 (8.9) |
Diabetes mellitus | 335 (8.9) | 71 (2.7) | 40 (3.1) |
≥ 65 yearsa | 632 (16.8) | 101 (3.8) | 6 (0.5) |
BMI ≥ 30 kg/m2 | 1100 (29.2) | 496 (18.8) | 266 (20.4) |
History of malignancy | 52 (1.4) | 27 (1.0) | 17 (1.3) |
Severe mobility impairment (EQ-5D)b | 468 (12.4) | 51 (1.9) | 4 (0.3) |
Any of 9 risk factorsc | 2619 (69.5) | 1373 (52.1) | 659 (50.6) |